Poland · Delayed Price · Currency is PLN Bioceltix Statistics
Total Valuation
Bioceltix has a market cap or net worth of PLN 394.94 million. The enterprise value is 371.40 million.
| Market Cap | 394.94M |
| Enterprise Value | 371.40M |
Important Dates
The next estimated earnings date is Tuesday, April 28, 2026.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 25.36% in one year.
| Current Share Class | 4.92M |
| Shares Outstanding | 4.92M |
| Shares Change (YoY) | +25.36% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.43% |
| Owned by Institutions (%) | 22.63% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 14.63 |
| P/TBV Ratio | 14.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.11 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -28.29 |
Financial Position
The company has a current ratio of 8.83, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.83 |
| Quick Ratio | 8.51 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -80.18 |
Financial Efficiency
Return on equity (ROE) is -43.22% and return on invested capital (ROIC) is -26.86%.
| Return on Equity (ROE) | -43.22% |
| Return on Assets (ROA) | -25.14% |
| Return on Invested Capital (ROIC) | -26.86% |
| Return on Capital Employed (ROCE) | -55.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -360,688 |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | 84.10 |
Taxes
| Income Tax | -51,492 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.45% in the last 52 weeks. The beta is 1.19, so Bioceltix's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -8.45% |
| 50-Day Moving Average | 89.99 |
| 200-Day Moving Average | 101.57 |
| Relative Strength Index (RSI) | 43.13 |
| Average Volume (20 Days) | 14,245 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.79M |
| Operating Income | -15.00M |
| Pretax Income | -14.84M |
| Net Income | -14.79M |
| EBITDA | -14.27M |
| EBIT | -15.00M |
| Earnings Per Share (EPS) | -2.89 |
Balance Sheet
The company has 23.95 million in cash and 405,023 in debt, with a net cash position of 23.55 million or 4.78 per share.
| Cash & Cash Equivalents | 23.95M |
| Total Debt | 405,023 |
| Net Cash | 23.55M |
| Net Cash Per Share | 4.78 |
| Equity (Book Value) | 27.00M |
| Book Value Per Share | 5.48 |
| Working Capital | 23.26M |
Cash Flow
In the last 12 months, operating cash flow was -11.49 million and capital expenditures -1.64 million, giving a free cash flow of -13.13 million.
| Operating Cash Flow | -11.49M |
| Capital Expenditures | -1.64M |
| Free Cash Flow | -13.13M |
| FCF Per Share | -2.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioceltix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.36% |
| Shareholder Yield | -25.36% |
| Earnings Yield | -3.74% |
| FCF Yield | -3.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |